Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen plans two September 2026 healthcare conference webcasts with management fireside chats and 30-day online replays for investors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surrozen (SRZN) will present at two upcoming healthcare investor conferences in September 2026. Management will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10 at 6:10 AM Pacific / 9:10 AM Eastern. A second fireside chat is scheduled at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16 at 10:50 AM Pacific / 1:50 PM Eastern. Live audio webcasts and replays will be available through the Investors section of Surrozen’s website for at least 30 days.
Details
News Market Reaction – SRZN
On Sep 3, the first trading day after this news, SRZN closed 0.27% below the previous close.
Data tracked by StockTitan Argus for the Sep 3 session.
Key Figures
- Upcoming conferences
- 2 conferences
- 2026 healthcare investor conferences
- Cantor conference date
- September 10, 2026
- 2026 Cantor Global Healthcare Conference
- Cantor fireside chat
- 6:10 AM Pacific Time / 9:10 AM Eastern Time
- September 10, 2026
- Morgan Stanley conference date
- September 16, 2026
- Morgan Stanley 24th Annual Global Healthcare Conference
- Morgan Stanley fireside chat
- 10:50 AM Pacific Time / 1:50 PM Eastern Time
- September 16, 2026
- Webcast replay
- At least 30 days
- Archived on the company website
Historical Context
-
Q2 results included collaboration revenue growth and a reported $50.2 million net income.
-
Management announced a July 22 H.C. Wainwright ophthalmology conference fireside chat.
-
Management announced participation in the H.C. Wainwright BioConnect investor conference.
-
Q1 results included a $127.5 million net loss and $106.9 million cash balance.
-
Surrozen granted a 2,020-share employee stock option under its inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
wnt signaling medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences.
2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026
Fireside Chat at 6:10 AM Pacific Time/9:10 AM Eastern Time
Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026
Fireside Chat at 10:50 AM Pacific Time/1:50 PM Eastern Time
Interested parties may access the audio webcasts for the conferences via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcasts will be archived on the website www.surrozen.com for at least 30 days.
About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, such as the Company’s plan to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, the availability of data, such as initial data from the DUET study being anticipated in the second half of 2027, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates); Surrozen’s intention to submit an IND application for SZN-8141 by the end of the third quarter of 2026; and expectations regarding Surrozen’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: Investorinfo@surrozen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Surrozen (SRZN) present at the 2026 Cantor Global Healthcare Conference?
Surrozen management will present at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, in a fireside chat scheduled for 6:10 AM Pacific Time / 9:10 AM Eastern Time.
What is the date and time of Surrozen's fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference?
Surrozen is scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 10:50 AM Pacific Time / 1:50 PM Eastern Time.
How can investors access the Surrozen (SRZN) webcasts for the September 2026 conferences?
Interested parties can access the live audio webcasts for both conferences via the Investors section of the Surrozen website at the events calendar page.
Will replays of the Surrozen September 2026 conference webcasts be available?
Yes. Replays of the Surrozen conference webcasts will be archived on www.surrozen.com for at least 30 days after the events.